These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24490149)

  • 1. Multiclass prediction with partial least square regression for gene expression data: applications in breast cancer intrinsic taxonomy.
    Huang CC; Tu SH; Huang CS; Lien HH; Lai LC; Chuang EY
    Biomed Res Int; 2013; 2013():248648. PubMed ID: 24490149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction consistency and clinical presentations of breast cancer molecular subtypes for Han Chinese population.
    Huang CC; Tu SH; Lien HH; Jeng JY; Liu JS; Huang CS; Wu YY; Liu CY; Lai LC; Chuang EY
    J Transl Med; 2012 Sep; 10 Suppl 1(Suppl 1):S10. PubMed ID: 23046482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular subtyping of breast cancer intrinsic taxonomy with oligonucleotide microarray and NanoString nCounter.
    Chen YJ; Huang CS; Phan NN; Lu TP; Liu CY; Huang CJ; Chiu JH; Tseng LM; Huang CC
    Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34387660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.
    Milioli HH; Vimieiro R; Riveros C; Tishchenko I; Berretta R; Moscato P
    PLoS One; 2015; 10(7):e0129711. PubMed ID: 26132585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research-based PAM50 signature and long-term breast cancer survival.
    Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
    Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
    Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
    BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machine learning for RNA sequencing-based intrinsic subtyping of breast cancer.
    Cascianelli S; Molineris I; Isella C; Masseroli M; Medico E
    Sci Rep; 2020 Aug; 10(1):14071. PubMed ID: 32826944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of intrinsic subtype ambiguity in Luminal A breast cancer and its relationship to clinical outcomes.
    Kumar N; Zhao D; Bhaumik D; Sethi A; Gann PH
    BMC Cancer; 2019 Mar; 19(1):215. PubMed ID: 30849944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CrossLink: a novel method for cross-condition classification of cancer subtypes.
    Ma C; Sastry KS; Flore M; Gehani S; Al-Bozom I; Feng Y; Serpedin E; Chouchane L; Chen Y; Huang Y
    BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):549. PubMed ID: 27556419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a 6-gene signature for the survival prediction of breast cancer patients based on integrated multi-omics data analysis.
    Mo W; Ding Y; Zhao S; Zou D; Ding X
    PLoS One; 2020; 15(11):e0241924. PubMed ID: 33170908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
    Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.
    Cejalvo JM; Martínez de Dueñas E; Galván P; García-Recio S; Burgués Gasión O; Paré L; Antolín S; Martinello R; Blancas I; Adamo B; Guerrero-Zotano Á; Muñoz M; Nucíforo P; Vidal M; Pérez RM; Chacón López-Muniz JI; Caballero R; Peg V; Carrasco E; Rojo F; Perou CM; Cortés J; Adamo V; Albanell J; Gomis RR; Lluch A; Prat A
    Cancer Res; 2017 May; 77(9):2213-2221. PubMed ID: 28249905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases.
    Bustamante Eduardo M; Popovici V; Imboden S; Aebi S; Ballabio N; Altermatt HJ; Günthert A; Jaggi R
    BMC Cancer; 2019 Jun; 19(1):549. PubMed ID: 31174485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A three-gene model to robustly identify breast cancer molecular subtypes.
    Haibe-Kains B; Desmedt C; Loi S; Culhane AC; Bontempi G; Quackenbush J; Sotiriou C
    J Natl Cancer Inst; 2012 Feb; 104(4):311-25. PubMed ID: 22262870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.
    Prat A; Parker JS; Fan C; Perou CM
    Breast Cancer Res Treat; 2012 Aug; 135(1):301-6. PubMed ID: 22752290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absolute assignment of breast cancer intrinsic molecular subtype.
    Paquet ER; Hallett MT
    J Natl Cancer Inst; 2015 Jan; 107(1):357. PubMed ID: 25479802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.
    Caan BJ; Sweeney C; Habel LA; Kwan ML; Kroenke CH; Weltzien EK; Quesenberry CP; Castillo A; Factor RE; Kushi LH; Bernard PS
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):725-34. PubMed ID: 24521998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.